AI Science Tracker

University of Virginia

1 discovery from 2025

Discoveries

LogiRx predicts and tests an escitalopram pathway in cardiac hypertrophy

LogiRx, a mechanistic machine-learning model, predicted an off-target serotonin-receptor/PI3Kγ pathway for escitalopram’s antihypertrophic effect. The authors report mechanistic experiments in cultured cardiomyocytes, reduced hypertrophy in a mouse model, and retrospective patient-database associations. The drug and initial compound screen predated LogiRx; patient associations do not establish causation or clinical benefit.

Technology: LogiRx logic-based mechanistic machine learning

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Primary abstract reports experimental pathway validation, cardiomyocyte and mouse outcomes, and patient database associations.
  • Still unknown: Independent replication and broader application are not established by this bounded review.
  • AI role: LogiRx combines a mechanistic network and drug-target data to predict drug-induced pathways for experimental follow-up; the compound screen and drugs were prior inputs.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40035765/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Primary PubMed metadata/abstract and publisher full-text PDF indexed result; retrospective human association caveat preserved..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.